HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.

MLA

Milde, Till, et al. “HD-MB03 Is a Novel Group 3 Medulloblastoma Model Demonstrating Sensitivity to Histone Deacetylase Inhibitor Treatment.” Journal of Neuro-Oncology, vol. 110, no. 3, Dec. 2012, pp. 335–48. EBSCOhost, https://doi.org/10.1007/s11060-012-0978-1.

APA

Milde, T., Lodrini, M., Savelyeva, L., Korshunov, A., Kool, M., Brueckner, L. M., Antunes, A. S. L. M., Oehme, I., Pekrun, A., Pfister, S. M., Kulozik, A. E., Witt, O., & Deubzer, H. E. (2012). HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. Journal of Neuro-Oncology, 110(3), 335–348. https://doi.org/10.1007/s11060-012-0978-1

Chicago

Milde, Till, Marco Lodrini, Larissa Savelyeva, Andrey Korshunov, Marcel Kool, Lena M Brueckner, André S L M Antunes, et al. 2012. “HD-MB03 Is a Novel Group 3 Medulloblastoma Model Demonstrating Sensitivity to Histone Deacetylase Inhibitor Treatment.” Journal of Neuro-Oncology 110 (3): 335–48. doi:10.1007/s11060-012-0978-1.